CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Anakinra 149 MG/ML Prefilled Syringe [Kineret]Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2630 Vehicle + Heparin along with best supportive care Wiki 1.00
drug2589 Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. Wiki 1.00

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2/3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection

Phase 2/3 randomized, parallel group, 2-arm study (treatment vs. control), investigating the efficacy and safety of intravenous administration of anakinra, an interleukin 1 receptor antagonist ( IL-1), added to standard treatment, compared to standard treatment alone, to reduce hyperinflammation and respiratory distress in patients with SARS-CoV-2 infection.

NCT04443881 COVID-19 Pnemonia Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret]

Primary Outcomes

Description: Treatment success, defined as number of patients not requiring mechanical ventilation by Day 15.

Measure: Treatment success, defined as number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.

Time: Day 15

Description: Number of patients not requiring mechanical ventilation

Measure: Number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.

Time: Day 28

Description: Time to mechanical ventilation

Measure: Time to mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.

Time: Up to 28 days

Description: Time to oxygen saturation normalization

Measure: Time to oxygen saturation normalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.

Time: Up to 28 days

Description: Stay in ICU and hospitalization

Measure: Stay in ICU and hospitalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.

Time: Up to 28 days

Secondary Outcomes

Description: Total mortality rate

Measure: Total mortality rate to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.

Time: day 28

Description: Mortality 48 hours, 7 days, in ICU and hospital

Measure: Mortality 48 hours, 7 days, in ICU and hospital to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.

Time: 48 hours, 7 days

Description: Viral clearance / viral shedding

Measure: Viral clearance / viral shedding to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.

Time: Up to 28 days

Description: Frequency and severity of AEs: Treatment-emergent severe fatal and life-threatening serious adverse events (SAEs), Adverse events leading to premature discontinuation of study treatment, Anaphylactic/anaphylactoid reactions, Anakinra treatment group: Severe neutropenia, Treatment-emergent laboratory abnormalities.

Measure: To assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.

Time: At day 28

Other Outcomes

Description: Change (improvement) in IL-6

Measure: Change in IL-6 to assess the effect of anakinra on IL-6, ferritin, and selected biomarkers relevant for hyperinflammation, MAS and cytokine storm change from baseline.

Time: During 28 days

Description: Change (improvement) in ferritin

Measure: Change in ferritin to assess the effect of anakinra

Time: During 28 days

Description: Change (improvement) in D-dimer

Measure: Change in D-dimer to assess the effect of anakinra

Time: During 28 days

Description: Change (improvement) in TGs

Measure: Change in TGs to assess the effect of anakinra

Time: During 28 days

Description: Change (improvement) in lymphopenia

Measure: Change in lymphopenia to assess the effect of anakinra

Time: During 28 days

Description: Change (improvement) in CRP

Measure: Change in CRP to assess the effect of anakinra

Time: During 28 days

Description: Change (improvement) in ESR

Measure: Change in ESR to assess the effect of anakinra

Time: During 28 days

Description: Change (improvement) in LDH

Measure: Change in LDH to assess the effect of anakinra

Time: During 28 days

Description: Time to defervescence (fever end)

Measure: Time to defervescence to assess the effect of anakinra

Time: During 28 days


No related HPO nodes (Using clinical trials)